The Long-term Outlook for Essential Thrombocythemia

Campbell, Peter J.; Green, Anthony R.
February 2006
Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p157
Academic Journal
The article discusses the importance of studies on long-term consequences of essential thrombocythemia (ET), a myeloproliferative disorders. Such studies could provide diagnostic work-up and management approaches, comprehensive and complete clinical follow-up, and standardized end point evaluation. These advantages will enable physicians to assess the overall survival of patients with ET.


Related Articles

  • Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors. Wolanskyj, Alexandra P.; Schwager, Susan M.; Mcclure, Rebecca F.; Larson, Dirk R.; Tefferi, Ayalew // Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p159 

    OBJECTIVE: To describe the long-term natural history of essential thrombocythemia (ET) in terms of life expectancy, risk of disease transformation into a more aggressive myeloid disorder, and prognostic factors for both survival and disease complications. PATIENTS AND METHODS: The study...

  • Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Hong, Y.; Wang, G.; del Arroyo, A. Gutierrez; Hernandez, J.; Skene, C.; Erusalimsky, J. D. // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1117 

    Anagrelide (ANA) and hydroxycarbamide (HC) are two distinct pharmacological agents used to treat thrombocythaemia associated with myeloproliferative disorders. Although both drugs have been in clinical use for a number of years, comparative studies of their selectivity and mode of action are...

  • Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán, A.; Cervantes, F.; Bellosillo, B.; Giralt, M.; Juliá, A.; Hernández-Boluda, J. C.; Bosch, A.; Hernández-Nieto, L.; Clapés, V.; Burgaleta, C.; Salvador, C.; Arellano-Rodrigo, E.; Colomer, D.; Besses, C. // Leukemia (08876924);Jun2007, Vol. 21 Issue 6, p1218 

    The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range:...

  • Bone metabolism during interferon-alpha treatment of essential thrombocythemia. Kusec, Rajko; Kusec, Vesna; Gisslinger, Bettina; Woloszczuk, Wolfgang; Gisslinger, Heinz // Wiener Klinische Wochenschrift;2004, Vol. 116 Issue 1/2, p37 

    In-vitro studies have demonstrated that interferon (IFN) has an inhibitory effect on bone formation. Changes in bone metabolism were investigated in 19 patients treated for essential thrombocythemia with IFN-alpha. Serum biochemical parameters of bone remodeling [total alkaline phosphatase,...

  • Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations. Higgs, J. R.; Sadek, I.; Neumann, P. E.; Ing, V. W.; Renault, N. K.; Berman, J. N.; Greer, W. L. // Leukemia (08876924);Aug2008, Vol. 22 Issue 8, p1551 

    Essential thrombocythemia (ET) is a chronic myeloproliferative disorder, characterized by increased proliferation of megakaryocytes and elevated platelet count that usually occurs sporadically. We report a family with seven affected individuals in three generations, including one individual with...

  • Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Magnus Hultdin; Gunnel Sundström; Anders Wahlin; Berith Lundström; Jan Samuelsson; Gunnar Birgegård; Anna Engström-Laurent // Medical Oncology;Jan2007, Vol. 24 Issue 1, p63 

    Abstract  Anagrelide is a second-line option for reduction of thrombocythemia in patients with chronic myeloproliferative disorders (CMPDs). A multicenter, open, phase II study of anagrelide treatment in 60 patients during 2 yr was performed by the Swedish Myeloproliferative Disorder Study...

  • Myeloproliferative disorders: complications, survival and causes of death. Brodmann, S.; Passweg, J. R.; Gratwohl, A.; Tichelli, A.; Skoda, R. C. // Annals of Hematology;Jun2000, Vol. 79 Issue 6, p312 

    This retrospective single-center study compared thromboembolic and hemorrhagic complications, survival and causes of death in a cohort of 102 consecutive patients with myeloproliferative disorders (MPD). We included 17 patients with essential thrombocythemia (ET), 59 with polycythemia vera (PV),...

  • Long-term management of thrombocytosis in essential thrombocythaemia. Birgegård, Gunnar // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p1 

    Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder with a prolonged clinical course and a near-normal life expectancy. Therapy is stratified according to risk of thrombohaemorrhagic events. In high-risk patients, platelet reduction is generally recommended. In...

  • Epstein-Barr Virus Infection Associated With Bone Marrow Fibrin-Ring Granuloma. Hee-Jung Chung // American Journal of Clinical Pathology;Feb2010, Vol. 133 Issue 2, p300 

    We previously reported 24 cases of marrow fibrin-ring granuloma (FRG) encountered in 1 institution and concluded that, contrary to previous studies showing marrow FRG as a diagnostic marker for Q fever, Epstein-Barr virus (EBV) was the most common proven cause of such FRG. The present study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics